Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead GS-840 (adefovir dipivoxil) for HIV therapy on track for 1998 NDA, company tells Alex. Brown.

Executive Summary

GILEAD SCIENCES HOPING TO FILE 1998 NDA FOR HIV TREATMENT GS-840 (adefovir dipivoxil), Gilead Senior VP for Drug Development Howard Jaffe, MD, told an Alex. Brown analysts meeting in Baltimore. If a pivotal Phase II/III study underway "is positive, as we expect it to be, we anticipate filing an NDA in the first half of next year," Jaffe announced. The pivotal study, for which Gilead has completed accrual of 400 patients, will be completed this year, he said.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS030318

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel